Measles, Mumps and Rubella (MMR) Vaccines Market Challenges, opportunities, Key Regions reports, Drivers, key segment and Company Forecast 2018 – 2026
Measles, Mumps and Rubella (MMR) Vaccines Market |
Vaccines for measles, mumps, and rubella (MMR) are a mix of live viruses that are injected. While the immune system fights and protects against the infection, the live viruses are rendered inactive and unable to multiply in human cells. The MMR vaccine is effective for a long time. The MMR vaccine causes fever, rash, cough, bodily pain, headache, nausea, and serious side effects such as infection of the ovaries and testicles, deafness, and death in rare cases.
The global Measles, Mumps, and Rubella (MMR) Vaccines Market is being driven by an increase in the number of cases and prevalence of the disease. In many regions of the world, the disease is widespread. According to a 2014 report by the Centers for Disease Control and Prevention (CDC), 667 cases were documented in the United States from 27 states.
MMR vaccine development is being funded by both government and non-government organisations. The majority of persons who have not been immunised are infected with MMR. In addition, to prevent the disease from spreading, the Asia-Pacific area is developing awareness programmes and campaigns. Furthermore, the industry is predicted to rise due to strong regulations and patient safety. The government is working on eradicating the disease on a massive scale in order to have a long-term impact.
Market Segmentation:
By Product Type:
- Monovalent
- Combinational
- Divalent
- Trivalent
- Others
By End Users:
- Hospitals
- Healthcare Centers
- Others
Comments
Post a Comment